Detalhe da pesquisa
1.
Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
Ann Neurol
; 93(6): 1053-1068, 2023 06.
Artigo
Inglês
| MEDLINE | ID: mdl-36866852
2.
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable.
Brain
; 146(11): 4633-4644, 2023 11 02.
Artigo
Inglês
| MEDLINE | ID: mdl-37369086
3.
ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs.
Mult Scler
; 29(8): 904-925, 2023 07.
Artigo
Inglês
| MEDLINE | ID: mdl-37293841
4.
Diagnosis and treatment of progressive multiple sclerosis: A position paper.
Eur J Neurol
; 30(1): 9-21, 2023 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36209464
5.
European Committee for Treatment and Research in Multiple Sclerosis and European Academy of Neurology consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs.
Eur J Neurol
; 30(8): 2144-2176, 2023 08.
Artigo
Inglês
| MEDLINE | ID: mdl-37293849
6.
Multiple sclerosis in the era of COVID-19: disease course, DMTs and SARS-CoV2 vaccinations.
Curr Opin Neurol
; 35(3): 319-327, 2022 06 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35674075
7.
Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD.
Ann Neurol
; 89(6): 1088-1098, 2021 06.
Artigo
Inglês
| MEDLINE | ID: mdl-33586143
8.
Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension.
Mult Scler
; 28(3): 480-486, 2022 03.
Artigo
Inglês
| MEDLINE | ID: mdl-34498507
9.
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data.
Mult Scler
; 28(5): 842-846, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-34882037
10.
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.
Mult Scler
; 28(9): 1424-1456, 2022 08.
Artigo
Inglês
| MEDLINE | ID: mdl-35196927
11.
Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial.
Eur J Neurol
; 29(3): 790-801, 2022 03.
Artigo
Inglês
| MEDLINE | ID: mdl-34748672
12.
Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial.
Proc Natl Acad Sci U S A
; 116(17): 8463-8470, 2019 04 23.
Artigo
Inglês
| MEDLINE | ID: mdl-30962374
13.
A plea for equitable global access to COVID-19 diagnostics, vaccination and therapy: The NeuroCOVID-19 Task Force of the European Academy of Neurology.
Eur J Neurol
; 28(11): 3849-3855, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-33460486
14.
Risk and outcomes of COVID-19 in patients with multiple sclerosis.
Eur J Neurol
; 28(11): 3712-3721, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34152073
15.
Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey.
J Med Internet Res
; 23(10): e29558, 2021 10 06.
Artigo
Inglês
| MEDLINE | ID: mdl-34612826
16.
Highlights from the 2019 European Congress on Treatment and Research in Multiple Sclerosis (ECTRIMS 2019).
Mult Scler
; 26(7): 859-868, 2020 06.
Artigo
Inglês
| MEDLINE | ID: mdl-32364431
17.
Single-subject structural cortical networks in clinically isolated syndrome.
Mult Scler
; 26(11): 1392-1401, 2020 10.
Artigo
Inglês
| MEDLINE | ID: mdl-31339446
18.
Impact of 3 Tesla MRI on interobserver agreement in clinically isolated syndrome: A MAGNIMS multicentre study.
Mult Scler
; 25(3): 352-360, 2019 03.
Artigo
Inglês
| MEDLINE | ID: mdl-29327668
19.
Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.
Mult Scler
; 24(5): 642-652, 2018 04.
Artigo
Inglês
| MEDLINE | ID: mdl-28382837
20.
Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.
Brain
; 140(9): 2426-2443, 2017 Sep 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29050389